[
    [
        {
            "time": "",
            "original_text": "西,南,证,券,医,药,2,0,2,2,年,度,策,略,：,未,来,医,药,估,值,有,望,均,衡,，,“,穿,越,医,保,”,和,“,疫,情,脱,敏,”,是,两,条,核,心,主,线",
            "features": {
                "keywords": [
                    "医药",
                    "估值",
                    "均衡",
                    "穿越医保",
                    "疫情脱敏",
                    "核心主线"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "西,南,证,券,医,药,2,0,2,2,年,度,策,略,：,未,来,医,药,估,值,有,望,均,衡,，,“,穿,越,医,保,”,和,“,疫,情,脱,敏,”,是,两,条,核,心,主,线",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]